Klotho Neurosciences, Inc. operates with two divisions: Natural Resources and Cell and Gene Therapy. The Natural Resources division is focused on the exploration and development of the Skaergaard Project in Southeast Greenland, which is undeveloped palladium, gold, and platinum deposits. The Skaergaard Project is located in Southeast Greenland, which is an undeveloped palladium, gold, and platinum deposit. It operates three Mineral Exploration Licenses (MEL): MEL 2007-01, MEL 2012-25, and MEL 2021-10. The Cell and Gene Therapy division includes the Company's KLTO-202 primary indication for amyotrophic lateral sclerosis (ALS or Lou Gehrig’s Disease). It is engaged in developing and providing new therapies to alleviate and/or reverse the progression of neurodegenerative diseases through the use of cell and gene therapy. It is also focusing on developing therapeutic agents for the treatments for Alzheimer's and Parkinson's disease.